305 related articles for article (PubMed ID: 12756080)
21. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Castellano I; Cassoni P; Ricardi U; Munoz F; Racca P; Contu V; Beltramo G; Morino M; Mussa A
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):73-8. PubMed ID: 19632066
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
23. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
Ozawa Y; Hara M; Sakurai K; Nakagawa M; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
[TBL] [Abstract][Full Text] [Related]
25. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
27. [Contribution of positron emission tomography to the detection and staging of breast cancer].
Domínguez ML; Suárez JP; Maldonado A; García-Bernardo L; García-Rico E; Cornide M; de las Heras PM; Serna JA; Ortega F
Cir Esp; 2005 May; 77(5):271-9. PubMed ID: 16420933
[TBL] [Abstract][Full Text] [Related]
28. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
[TBL] [Abstract][Full Text] [Related]
29. Fluorodeoxyglucose-PET in the management of breast cancer.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
He X; Sun L; Huo Y; Shao M; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
[TBL] [Abstract][Full Text] [Related]
31. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
Siggelkow W; Rath W; Buell U; Zimny M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
[TBL] [Abstract][Full Text] [Related]
33. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
34. Performance of FDG PET/CT in the clinical management of breast cancer.
Groheux D; Espié M; Giacchetti S; Hindié E
Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
[TBL] [Abstract][Full Text] [Related]
35. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
[TBL] [Abstract][Full Text] [Related]
36. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
37. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
38. Update on detection of sentinel lymph nodes in patients with breast cancer.
Aarsvold JN; Alazraki NP
Semin Nucl Med; 2005 Apr; 35(2):116-28. PubMed ID: 15765374
[TBL] [Abstract][Full Text] [Related]
39. [The role of preoperative investigation with 18-FDG-PET/CT in primary operable breast cancer].
Garami Z; Hascsi Z; Garai I; Tanyi M; Lukács G; Damjanovich L
Magy Seb; 2009 Jun; 62(3):107-12. PubMed ID: 19525175
[TBL] [Abstract][Full Text] [Related]
40. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]